SoFi stock falls after announcing $1.5B public offering of common stock
Investing.com - Morgan Stanley has assumed coverage on IQVIA Holdings (NYSE:IQV) with an Overweight rating and a price target of $265.00, representing a 16% upside from the current price of $228.49. This aligns with the broader analyst sentiment, as InvestingPro data shows 10 analysts have recently revised their earnings estimates upward for the upcoming period.
The research firm indicated it expects "decent demand for clinical stage CRO work in 2026," with this outlook supported by bullish views from its survey work. This positive outlook comes as IQVIA has demonstrated strong momentum, with a remarkable 63.91% price return over the past six months.
Morgan Stanley noted that IQVIA’s Technology & Analytics Solutions (TAS) provides the company with leading positions in diversified and sticky end markets.
The price target of $265.00 was derived from an EV/EBITDA multiple of 14.5x on Morgan Stanley’s 2026 estimates for the company.
The firm believes IQVIA’s valuation "screens attractive relative to peers," according to its coverage assumption note published Monday.
In other recent news, IQVIA Holdings Inc. reported its third-quarter earnings for 2025, which surpassed analyst expectations. The company achieved an adjusted diluted earnings per share (EPS) of $3.00, slightly above the projected $2.97, and recorded revenue of $4.1 billion, exceeding the anticipated $4.08 billion. In addition to these financial results, IQVIA announced the appointment of Nobel laureate Dr. William G. Kaelin Jr. to its board of directors, effective immediately. This appointment is a significant development for the company, given Dr. Kaelin’s esteemed background in medicine and research.
Further developments include changes in analyst ratings for IQVIA. Baird upgraded the company’s stock rating from Neutral to Outperform, citing a moderately improving environment in the research and development sector as a reason for the upgrade. Conversely, TD Cowen downgraded the stock from Buy to Hold, although it raised the price target to $215.00, due to valuation concerns. Additionally, NEXT Oncology, an Avacare business, expanded its Phase I cancer clinical trial services to Japan through a partnership with Kansai Medical University in Osaka. These recent developments reflect ongoing strategic movements and analyst perspectives concerning IQVIA and its industry landscape.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.